AGEN


Company Update (NASDAQ:AGEN): Here’s Why Agenus Inc Shares Are Tumbling Today

Agenus Inc (NASDAQ:AGEN) saw its shares tumbling over 8% today, after H.C.

H.C. Wainwright Weighs In on Agenus Inc (AGEN) Following 2Q:16 Update

In a research report released Friday, H.C.

Stock Update (NASDAQ:AGEN): Agenus Inc Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors

Agenus Inc (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company’s …

Company Update (NASDAQ:AGEN): Agenus Inc Announces Clearance of Investigational NDA by the FDA for anti-CTLA-4 and anti-GITR Antibodies

Agenus Inc (NASDAQ:AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, announced today that the U.S.

Company Update (NASDAQ:AGEN): Agenus Inc Completes XOMA Antibody Manufacturing Pilot Plant Acquisition

Agenus Inc (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that it has completed the previously announced acquisition of …

Tuesday Morning’s Market Insights: Alibaba Group Holding Ltd (BABA), Yahoo! Inc. (YHOO), GW Pharmaceuticals PLC- ADR (GWPH) and Agenus Inc (AGEN)

Alibaba Group Holding Ltd (NYSE:BABA) is up 8.32% in pre-market trading up to $82.

William Blair Offers Commentary On Agenus Inc (AGEN) Following $115 Million Royalty Deal

William Blair’s healthcare analyst John Sonnier weighed in with a few insights on Agenus Inc (NASDAQ:AGEN), as the company yesterday announced a transaction with an investor group …

Company Update (NASDAQ:AGEN): GlaxoSmithKline’s Malaria Vaccine Containing Agenus Inc’s QS-21 Stimulon® Receives Positive Opinion from European Regulators

Agenus Inc (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, announced that GlaxoSmithKline plc (ADR) (NYSE:GSK) received a …

Company Update (NASDAQ:AGEN): Agenus Inc Acquires Novel Antibodies to Immuno-oncology Target CEACAM1

Agenus Inc (NASDAQ:AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced that it has acquired rights to antibodies targeting …

Oppenheimer Initiates Coverage on Agenus Inc Following Collaborations With Merck & Co., Inc. and Incyte Corporation

Oppenheimer analyst Christopher Marai initiated coverage on Agenus Inc (NASDAQ:AGEN) after the company began collaborations with Merck and Incyte for the discovery and development of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts